Stem Cell Transplant into Preimplantation Embryo Yields Myocardial Infarction-Resistant Adult Phenotype

Authors

  • Satsuki Yamada,

    1. Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Rochester, Minnesota, USA
    2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    3. Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
    Search for more papers by this author
  • Timothy J. Nelson,

    1. Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Rochester, Minnesota, USA
    2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    3. Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
    Search for more papers by this author
  • Atta Behfar,

    1. Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Rochester, Minnesota, USA
    2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    3. Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
    Search for more papers by this author
  • Ruben J. Crespo-Diaz,

    1. Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Rochester, Minnesota, USA
    2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    3. Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
    Search for more papers by this author
  • Diego Fraidenraich,

    1. Department of Cell Biology and Molecular Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA
    Search for more papers by this author
  • Andre Terzic

    Corresponding author
    1. Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Rochester, Minnesota, USA
    2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    3. Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
    • Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Search for more papers by this author
    • Telephone: 507-2842747; Fax: 507-2669936


  • Author contributions: S.Y.: conception and design, provision of study material, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; T.J.N.: conception and design, provision of study material, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; A.B.: conception and design, provision of study material, collection and assembly of data, data analysis and interpretation, final approval of manuscript; R.J.C.D.: provision of study material, collection and assembly of data, final approval of manuscript; D.F.: conception and design, provision of study material, data analysis and interpretation, administrative support, manuscript writing, final approval of manuscript; AT: conception and design, data analysis and interpretation, administrative support, manuscript writing, final approval of manuscript.

  • First published online in STEM CELLS EXPRESS May 14, 2009.

Abstract

Stem cells are an emerging strategy for treatment of myocardial infarction, limited however to postinjury intervention. Preventive stem cell-based therapy to augment stress tolerance has yet to be considered for lifelong protection. Here, pluripotent stem cells were microsurgically introduced at the blastocyst stage of murine embryo development to ensure stochastic integration and sustained organ contribution. Engineered chimera displayed excess in body weight due to increased fat deposits, but were otherwise devoid of obesity-related morbidity. Remarkably, and in sharp contrast to susceptible nonchimeric offspring, chimera was resistant to myocardial infarction induced by permanent coronary occlusion. Infarcted nonchimeric adult hearts demonstrated progressive deterioration in ejection fraction, while age-matched 12–14-months-old chimera recovered from equivalent ischemic insult to regain within one-month preocclusion contractile performance. Electrical remodeling and ventricular enlargement with fibrosis, prominent in failing nonchimera, were averted in the chimeric cohort characterized by an increased stem cell load in adipose tissue and upregulated markers of biogenesis Ki67, c-Kit, and stem cell antigen-1 in the myocardium. Favorable outcome in infarcted chimera translated into an overall benefit in workload capacity and survival. Thus, prenatal stem cell transplant yields a cardioprotective phenotype in adulthood, expanding cell-based indications beyond traditional postinjury applications to include pre-emptive therapy. STEM CELLS 2009;27:1697–1705

Ancillary